We narrowed to 5,982 results for: actin
-
Viral prep#37825-AAV1.TPurposeReady-to-use AAV1 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFPAvailable sinceMay 29, 2019AvailabilityAcademic Institutions and Nonprofits only
-
pCAG_GPHN.FingR-eGFP-CCR5TC
Plasmid#46296DepositorAvailable sinceJuly 25, 2013AvailabilityAcademic Institutions and Nonprofits onlyCited by -
pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (AAV9)
Viral prep#100835-AAV9PurposeReady-to-use AAV9 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGAvailable sinceMay 11, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-tdTomato (codon diversified) (AAV2)
Viral prep#59462-AAV2PurposeReady-to-use AAV2 particles produced from pAAV-CAG-tdTomato (codon diversified) (#59462). In addition to the viral particles, you will also receive purified pAAV-CAG-tdTomato (codon diversified) plasmid DNA. CAG-driven tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (codon diversified)Available sinceApril 25, 2019AvailabilityAcademic Institutions and Nonprofits only -
pCAG:GPI-GFP
Plasmid#32601DepositorPublicationInsertGPI-GFP
ExpressionMammalianPromoterCAGAvailable sinceMarch 27, 2015AvailabilityAcademic Institutions and Nonprofits onlyCited by -
pAAV-FLEX-tdTomato (AAV5)
Viral prep#28306-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (Cre-dependent)Available sinceAug. 4, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-NLS-GFP (AAV PHP.eB)
Viral prep#104061-PHPeBPurposeReady-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFPAvailable sinceMarch 5, 2019AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (AAV Retrograde)
Viral prep#84445-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-drive, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFP (Cre-dependent)Available sinceOct. 12, 2017AvailabilityAcademic Institutions and Nonprofits only -
AAV-FLEX-Arch-GFP
Plasmid#22222PurposeCre-dependent viral expression of Arch-GFP for neuronal inhibitionDepositorPublicationHas serviceAAV1 and AAV9InsertArch
UseAAV and Cre/Lox; Adeno-associated virusTagsGFPExpressionMammalianMutationnoPromoterCAGAvailable sinceJan. 6, 2010AvailabilityAcademic Institutions and Nonprofits onlyCited by -
pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (AAV1)
Viral prep#75470-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry (#75470). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEXFRT-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, Flp recombinase-dependent expression of channelrhodopsin H134R mutant fused to mCherry. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsmCherryAvailable sinceMarch 2, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-tdTomato (codon diversified) (AAV5)
Viral prep#59462-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-CAG-tdTomato (codon diversified) (#59462). In addition to the viral particles, you will also receive purified pAAV-CAG-tdTomato (codon diversified) plasmid DNA. CAG-driven tdTomato expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagstdTomato (codon diversified)Available sinceOct. 19, 2016AvailabilityAcademic Institutions and Nonprofits only -
pCAG HRP-TM
Plasmid#44441DepositorPublicationInsertHorseradish peroxidase fused to the transmembrane domain of PDGFR
TagsHA tag and myc tagExpressionMammalianPromoterCAGAvailable sinceApril 24, 2013AvailabilityAcademic Institutions and Nonprofits onlyCited by -
pAAV-CAG-dLight1.3b (AAV5)
Viral prep#125560-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGAvailable sinceOct. 15, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CAG-GFP (AAV2 trial size)
Viral prep#37825-AAV2.TPurposeReady-to-use AAV2 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsGFPAvailable sinceMay 29, 2019AvailabilityAcademic Institutions and Nonprofits only -
pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (AAV5)
Viral prep#100835-AAV5PurposeReady-to-use AAV5 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGAvailable sinceMay 11, 2018AvailabilityAcademic Institutions and Nonprofits only -
pCAG-CBE4max-SpG-P2A-EGFP (RTW4552)
Plasmid#139998PurposeCAG promoter expression plasmid for human codon optimized BE4max C-to-T base editor with SpG(D10A/D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R) and P2A-EGFPDepositorInserthuman codon optimized CBE4max SpCas9 variant named SpG with P2A-EGFP
UseCRISPRTagsP2A-EGFPExpressionMammalianMutationnSpCas9=D10A; SpG=D1135L/S1136W/G1218K/E1219Q/R13…PromoterCAGAvailable sinceMarch 26, 2020AvailabilityAcademic Institutions and Nonprofits onlyCited by -
AAV pCAG-FLEX-EGFP-WPRE (AAV5)
Viral prep#51502-AAV5PurposeReady-to-use AAV5 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCAGTagsEGFP (Cre-dependent)Available sinceOct. 3, 2019AvailabilityAcademic Institutions and Nonprofits only -
mCherry-Actin-7
Plasmid#54966PurposeLocalization: Actin, Excitation: 587, Emission: 610DepositorAvailable sinceOct. 7, 2014AvailabilityAcademic Institutions and Nonprofits onlyCited by -
mCherry-Actin-3
Plasmid#54965PurposeLocalization: Actin, Excitation: 587, Emission: 610DepositorAvailable sinceSept. 17, 2014AvailabilityAcademic Institutions and Nonprofits onlyCited by -
tFucci(SA)5
Plasmid#153520PurposeNew color variant of Fucci (Fluorescent ubiquitination-based cell cycle indicator) : Fucci(SA)5.DepositorInserttFucci(SA)5.
TagsAzaleaB5-hCdt1(30/120)_P2A_h2-3-hGem(1/110)ExpressionBacterial and MammalianPromoterCAGAvailable sinceAug. 20, 2020AvailabilityAcademic Institutions and Nonprofits onlyCited by